Psychedelic Therapy for Anxiety
Anxiety disorders — including generalized anxiety, social anxiety, and end-of-life anxiety — are being studied across multiple psychedelic substances. Definium Therapeutics' LSD analogue MM-120 showed strong Phase 2 results for generalized anxiety disorder. Psilocybin shows particular promise for existential anxiety in cancer patients, with landmark trials at NYU and Johns Hopkins demonstrating rapid and lasting relief.
Unlike traditional anxiolytics that require ongoing daily use, psychedelic-assisted therapy aims to address anxiety at a psychological root level. Researchers hypothesize that the altered state allows patients to reprocess fear responses and gain new perspectives on anxiety-provoking situations.
Clinical Trials
14 trials currently recruiting
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
Cybin IRL Limited
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
Joshua Woolley, MD, PhD
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
Field Trip Health
Impact of Pre-Sedation Virtual Reality Game on Post-Discharge Negative Behaviors in the Pediatric Emergency Department
Medical College of Wisconsin
Correlates of Anxiety Associated With a Life-threatening Illness
Lykos Therapeutics
MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
Lykos Therapeutics
Companies & Research
Organizations with active anxiety research programs